A PET study to determine biodistribution and binding characteristics of [11^C]AZ14132516 in healthy participants

Study identifier:D9690C00003

ClinicalTrials.gov identifier:NCT05818514

EudraCT identifier:N/A

CTIS identifier:2022-502843-36-00

Study Complete

Official Title

A Phase 0 Open Label Positron Emission Tomography Study to Assess the Biodistribution and Binding Characteristics of [11^C]AZ14132516 Following Administration to Healthy Participants

Medical condition

Healthy Volunteers

Phase

N/A

Healthy volunteers

Yes

Study drug

[11^C]AZ14132516

Sex

All

Actual Enrollment

8

Study type

Interventional

Age

n/a - n/a

Date

Study Start Date: 27 Apr 2023
Primary Completion Date: 11 Jul 2023
Study Completion Date: 11 Jul 2023

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Sequential Assignment
Masking: -
Primary Purpose: Basic Science

Verification:

Verified 01 Jun 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria